Unresectable Hepatocellular Carcinoma Clinical Trial
Official title:
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nivolumab and ipilimumab may be effective in killing tumor cells in patients with liver cancer.
PRIMARY OBJECTIVE: I. To investigate the confirmed objective response rate (ORR) of nivolumab and ipilimumab in patients with hepatocellular carcinoma (HCC) who have progressed radiographically on atezolizumab/bevacizumab that necessitates change in treatment. SECONDARY OBJECTIVES: I. To determine the overall survival (OS) in hepatocellular carcinoma (HCC) patients treated with nivolumab and ipilimumab who have progressed radiographically on atezolizumab / bevacizumab that necessitates change in treatment. II. To determine the progression free survival (PFS) in hepatocellular carcinoma (HCC) patients treated with nivolumab and ipilimumab who have progressed radiographically on atezolizumab/bevacizumab that necessitates change in treatment. III. To determine the disease control rate in hepatocellular carcinoma (HCC) patients treated with nivolumab and ipilimumab who have progressed radiographically on atezolizumab/bevacizumab that necessitates change in treatment. IV. To assess the frequency and severity of adverse events in hepatocellular carcinoma (HCC) patients treated with nivolumab and ipilimumab who have progressed radiographically on atezolizumab/bevacizumab that necessitates change in treatment. OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 2 years from registration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00988741 -
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
|
Phase 2 | |
| Recruiting |
NCT03942328 -
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT06315101 -
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
|
||
| Not yet recruiting |
NCT04947956 -
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
|
||
| Completed |
NCT01004978 -
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
| Terminated |
NCT03695250 -
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02006030 -
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03896646 -
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
|
N/A | |
| Recruiting |
NCT05135364 -
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
|
Phase 2 | |
| Recruiting |
NCT06117891 -
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
|
||
| Recruiting |
NCT05957640 -
Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04736121 -
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
|
N/A | |
| Recruiting |
NCT05168163 -
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT03345225 -
A Clinical Study of Precision TACE (P-TACE) With Surefire
|
N/A | |
| Recruiting |
NCT05667064 -
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
|
||
| Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02989870 -
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
|
Phase 1 |